+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacovigilance Market - Global Forecast 2026-2032- Product Image
Pharmacovigilance Market - Global Forecast 2026-2032- Product Image
Sale

Pharmacovigilance Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5306611
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmacovigilance Market is projected to reach USD 13.71 Billion in 2026. It is expected to continue growing at a CAGR of 16.34%, reaching USD 34.17 Billion by 2032.

Pharmacovigilance has moved from a back-office compliance function to a strategic capability for protecting patients, preserving product value, and meeting global drug safety obligations. As regulators expand expectations for adverse event reporting, risk management plans, periodic benefit-risk evaluation reports, and post-marketing surveillance, life sciences organizations are prioritizing faster case intake, stronger signal detection, and auditable safety governance.

The pharmacovigilance landscape is shaped by rising medicine utilization, complex biologics and vaccines, expanding clinical trial activity, and larger volumes of real-world safety data from electronic health records, claims, patient support programs, call centers, literature, social media, and digital health channels. Organizations that can convert these data streams into validated individual case safety reports, risk signals, and compliant regulatory submissions are better positioned to maintain inspection readiness, strengthen benefit-risk management, and improve patient outcomes.

Transformative Shifts in the Pharmacovigilance Landscape

The pharmacovigilance landscape is being transformed by regulatory harmonization, digitized safety operations, and a shift toward proactive benefit-risk management. Standards such as ICH E2B(R3), MedDRA coding, EU Good Pharmacovigilance Practices, FDA post-market reporting expectations, and WHO safety monitoring principles are encouraging more structured, interoperable, and traceable safety data exchange across global safety systems.

At the same time, safety teams are absorbing higher reporting volumes from specialty drugs, biologics, vaccines, combination products, social listening programs, digital therapeutics, telehealth, and patient engagement platforms. This is pushing sponsors and service providers to redesign operating models around automation, quality-by-design, global case processing hubs, local affiliate oversight, medical safety review, and integrated signal management to support timely regulatory compliance and patient safety decisions.

Cumulative Impact of Artificial Intelligence on Drug Safety

Artificial intelligence is having a cumulative impact across pharmacovigilance by improving the speed, consistency, and traceability of routine workflows. Natural language processing, machine learning classification, entity extraction, duplicate detection, automated narrative drafting, intelligent MedDRA coding, and literature screening can reduce manual effort in case intake, triage, and quality control when implemented with validated rules and human oversight.

The strongest use cases are emerging where AI supports, rather than replaces, qualified safety professionals. Regulators continue to expect explainability, audit trails, documented validation, data privacy safeguards, and medical judgment for causality assessment, seriousness evaluation, expectedness review, and signal detection. As a result, AI adoption is most effective when embedded in governed safety systems that align with GxP quality standards, risk-based validation, cybersecurity controls, and transparent change management.

Key Regional Insights for Pharmacovigilance

Asia-Pacific is gaining importance as China, India, Japan, South Korea, Australia, and ASEAN markets expand clinical development, generic and biosimilar manufacturing, and national adverse event reporting systems. Regulatory authorities across the region are increasing expectations for local case reporting, risk management, and post-authorization safety monitoring, making regional pharmacovigilance coordination critical for sponsors operating across diverse languages, formats, and timelines. North America remains a mature center for pharmacovigilance innovation, supported by FDA FAERS, the Sentinel Initiative, REMS oversight, Health Canada reporting requirements, extensive clinical research activity, and established life sciences outsourcing capacity.

Latin America is strengthening post-marketing surveillance as Brazil, Mexico, and other markets modernize regulatory procedures and increase local safety reporting expectations. Europe continues to set a high bar through the European Medicines Agency, EudraVigilance, EU Good Pharmacovigilance Practices, formal risk management planning, and periodic safety reporting obligations. The Middle East is advancing national pharmacovigilance centers, electronic reporting, and local safety responsibilities as healthcare systems digitalize, while Africa is building medicine safety capacity through national regulatory authorities, WHO program participation, adverse event monitoring for vaccines and essential medicines, and stronger reliance-based regulatory collaboration as medicine access expands.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly aligned around regional reliance, local safety reporting, pharmacovigilance capacity building, and regulatory cooperation, making the bloc important for companies seeking scalable Asia-Pacific safety models. The GCC is advancing medicine safety oversight across Gulf states through regulatory coordination, hospital reporting systems, national health strategies, and digital health investments that generate more structured safety data for post-marketing surveillance.

The European Union remains the global benchmark for rigorous pharmacovigilance governance through centralized procedures, EudraVigilance, legally defined responsibilities for marketing authorization holders, qualified person requirements, and EU Good Pharmacovigilance Practices. BRICS countries represent strategically important demand because of large patient populations, domestic pharmaceutical manufacturing, expanding clinical research participation, and maturing surveillance systems. G7 markets continue to shape advanced standards for data integrity, inspection readiness, AI governance, real-world evidence, and benefit-risk transparency, while NATO countries add relevance through health security, medical countermeasure monitoring, supply resilience, and safety surveillance for critical medicines used in emergency preparedness.

Key Country Insights in Global Pharmacovigilance

The United States leads in large-scale post-market surveillance through FDA FAERS, Sentinel, REMS oversight, mandatory reporting obligations, and a mature ecosystem of pharmaceutical sponsors and safety service providers. Canada maintains strong pharmacovigilance requirements through Health Canada and its adverse reaction reporting framework, while Mexico and Brazil are important Latin American markets as COFEPRIS and ANVISA continue to strengthen medicine safety oversight, regulatory modernization, and local reporting practices.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central to clinical development, regulatory science, medical literature monitoring, and EU-aligned safety operations, with the United Kingdom operating through the MHRA and Yellow Card Scheme and EU members contributing to EudraVigilance-based surveillance. Russia requires localized regulatory attention due to national reporting expectations and local regulatory procedures. China and India are critical because of their scale in clinical research, manufacturing, pharmacovigilance program development, and patient populations; Japan and South Korea combine advanced regulatory systems with high adoption of structured safety data standards and strong post-marketing obligations; and Australia offers a mature, transparent system under the Therapeutic Goods Administration that supports regional pharmacovigilance planning across Asia-Pacific.

Actionable Recommendations for Pharmacovigilance Leaders

Industry leaders should prioritize a risk-based pharmacovigilance operating model that connects global safety databases, local affiliate processes, medical review, quality management, signal detection, and regulatory intelligence. Investing in interoperable platforms that support ICH E2B(R3), standardized MedDRA coding, automated case routing, literature screening, duplicate detection, audit trails, and compliant submissions can reduce cycle times while improving data quality and inspection readiness.

Organizations should also establish AI governance before scaling automation. Practical actions include validating algorithms, documenting model performance, preserving human medical oversight, monitoring bias, integrating privacy controls, maintaining vendor oversight, and training safety teams to work with intelligent workflow tools. Vendor partnerships should be assessed on inspection history, pharmacovigilance domain expertise, data security, multilingual coverage, regulatory submission capability, business continuity, and measurable quality outcomes.

Research Methodology

This executive summary is based on secondary research from publicly available regulatory guidance, international safety standards, national pharmacovigilance frameworks, and established industry practices. Core reference points include FDA post-marketing safety systems, EMA and EU GVP requirements, WHO pharmacovigilance principles, ICH safety data standards, MedDRA terminology practices, and country-level regulatory authority guidance.

The analysis applies a qualitative market intelligence approach, evaluating regulatory maturity, adverse event reporting infrastructure, technology adoption, outsourcing trends, clinical development activity, safety database interoperability, inspection expectations, and regional policy direction. Insights were synthesized to support strategic decision-making for pharmaceutical manufacturers, biotechnology companies, contract research organizations, pharmacovigilance service providers, medical affairs teams, and digital safety platform vendors without applying market sizing, market share, or forecast assumptions.

Conclusion

Pharmacovigilance is entering a more data-intensive and intelligence-led era in which speed, accuracy, interoperability, and transparency define operational advantage. Organizations that build modern safety architectures will be better prepared to manage global reporting complexity, detect emerging risks earlier, support compliant benefit-risk decisions, and maintain trusted relationships with regulators, clinicians, and patients.

As AI, real-world evidence, structured data standards, and harmonized regulatory expectations continue to mature, pharmacovigilance will increasingly support enterprise-wide benefit-risk strategy rather than isolated compliance tasks. Leaders that combine technology with medical expertise, quality discipline, validated governance, and regional regulatory intelligence can create resilient safety systems for the next generation of medicines.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pharmacovigilance Market, by Component
7.1. Introduction
7.2. Software
7.3. Services
8. Pharmacovigilance Market, by Type
8.1. Introduction
8.2. Cohort Event Monitoring
8.3. EHR Mining
8.4. Intensified ADR Reporting
8.5. Spontaneous Reporting
8.6. Targeted Spontaneous Reporting
9. Pharmacovigilance Market, by Product Life Cycle
9.1. Introduction
9.2. Phase I
9.3. Phase II
9.4. Phase III
9.5. Phase IV
9.6. Pre-clinical
10. Pharmacovigilance Market, by Delivery Mode
10.1. Introduction
10.2. In-house
10.3. Outsourced
11. Pharmacovigilance Market, by Process Flow
11.1. Introduction
11.2. Case Data Management
11.2.1. Case Data Analysis
11.2.2. Case Logging
11.2.3. Medical Reviewing & Reporting
11.3. Risk Management System
11.3.1. Risk Evaluation System
11.3.2. Risk Mitigation System
11.4. Signal Detection
11.4.1. Adverse Event Analysis
11.4.2. Adverse Event Logging
11.4.3. Adverse Event Review & Reporting
12. Pharmacovigilance Market, by Application
12.1. Introduction
12.2. Cardiovascular
12.3. Infectious Diseases
12.4. Neurology
12.5. Oncology
12.6. Respiratory
13. Pharmacovigilance Market, by End-user
13.1. Introduction
13.2. Biotechnology Companies
13.3. Medical Device Manufacturers
13.4. Pharmaceuticals
14. Pharmacovigilance Market, by Deployment Model
14.1. Introduction
14.2. On-Premises
14.3. Cloud-Based
14.4. Hybrid
15. Pharmacovigilance Market, by Region
15.1. Asia-Pacific
15.2. North America
15.3. Latin America
15.4. Europe
15.5. Middle East
15.6. Africa
16. Pharmacovigilance Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Pharmacovigilance Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Accenture, PLC
19.2. Bristol-Myers Squibb Company
19.3. Capgemini SE
19.4. ClinChoice
19.5. F. Hoffmann-La Roche AG
19.6. GlaxoSmithKline PLC
19.7. HCL Technologies Limited
19.8. ICON PLC
19.9. Infosys Limited
19.10. International Business Machines Corporation
19.11. IQVIA Inc.
19.12. ITclinical
19.13. Linical Co., Ltd.
19.14. Novartis AG
19.15. Oracle Corporation
19.16. Parexel International
19.17. Pfizer Inc.
19.18. Quanticate International limited
19.19. Sanofi S.A.
19.20. Syneos Health
19.21. TAKE Solutions Limited
19.22. TATA Consultancy Services Limited
19.23. Wipro Limited
List of Figures
FIGURE 1. GLOBAL PHARMACOVIGILANCE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PHARMACOVIGILANCE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL EHR MINING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL EHR MINING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL EHR MINING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PHASE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PHASE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PHASE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PRE-CLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PRE-CLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PRE-CLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL IN-HOUSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IN-HOUSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IN-HOUSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL OUTSOURCED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL OUTSOURCED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL OUTSOURCED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CASE LOGGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CASE LOGGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CASE LOGGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SIGNAL DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SIGNAL DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SIGNAL DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ON-PREMISES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ON-PREMISES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ON-PREMISES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CLOUD-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CLOUD-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL CLOUD-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HYBRID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HYBRID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HYBRID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 156. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 158. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 159. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 160. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 161. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 162. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 163. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 164. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 165. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 166. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 167. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 180. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 182. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 183. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 184. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 185. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 186. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 187. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 188. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 189. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 190. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 191. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 193. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 195. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 196. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 197. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 198. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 199. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 200. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 201. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 202. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 203. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 204. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 205. GCC PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. GCC PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 207. GCC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 208. GCC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 209. GCC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 210. GCC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 211. GCC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 212. GCC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 213. GCC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 214. GCC PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 215. GCC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 216. GCC PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 229. BRICS PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 230. BRICS PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 231. BRICS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 232. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 233. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 234. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 235. BRICS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 236. BRICS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 237. BRICS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 238. BRICS PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 239. BRICS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 240. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 241. G7 PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. G7 PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 243. G7 PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 244. G7 PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 245. G7 PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 246. G7 PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 247. G7 PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 248. G7 PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 249. G7 PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 250. G7 PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. G7 PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 252. G7 PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 253. NATO PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 254. NATO PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 255. NATO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 256. NATO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 257. NATO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 258. NATO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 259. NATO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 260. NATO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 261. NATO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 262. NATO PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. NATO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 264. NATO PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 265. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 278. CANADA PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. CANADA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 280. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 281. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 282. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 283. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 284. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 285. CANADA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 286. CANADA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 287. CANADA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 288. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 289. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 290. MEXICO PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 292. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 293. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 294. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 295. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 296. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 297. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 298. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 299. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 300. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 301. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 304. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 305. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 326. GERMANY PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 328. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 329. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 330. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 331. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 332. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 333. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 334. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 335. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 336. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 337. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 338. FRANCE PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 339. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 340. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 341. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 342. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 343. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 344. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 345. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 346. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 347. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 348. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 349. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 350. RUSSIA PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 351. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 352. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 353. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 354. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 355. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 356. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 357. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2017-2032 (USD MILLION)
TABLE 358. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2017-2032 (USD MILLION)
TABLE 359. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 360. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 361. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2017-2032 (USD MILLION)
TABLE 362. ITALY PHARMACOVIGILANCE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 363. ITALY PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 364. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 365. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2017-2032 (USD MILLION)
TABLE 366. ITALY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 367. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2017-2032 (USD MILLION)
TABLE 368. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABL

Companies Mentioned

  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.71 Billion
Forecasted Market Value ( USD ) by 2032 $ 34.17 Billion
Compound Annual Growth Rate16.3%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Pharmacovigilance & Drug Safety Software Market - Global Forecast 2026-2032 - Product Image

Pharmacovigilance & Drug Safety Software Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Pharmacovigilance - Global Strategic Business Report - Product Image

Pharmacovigilance - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Pharmacovigilance and Drug Safety Software - Global Strategic Business Report - Product Image

Pharmacovigilance and Drug Safety Software - Global Strategic Business Report

  • Report
  • 187 Pages
  • Global
From
Pharmacovigilance and Drug Safety Software Market Size, Share & Trends Analysis Report by Functionality (Case Data Collection and Management, Adverse Event Reporting and Analysis), Deployment (on Premise, on Demand), End Use and Region with Growth Forecasts, 2025-2033 - Product Image

Pharmacovigilance and Drug Safety Software Market Size, Share & Trends Analysis Report by Functionality (Case Data Collection and Management, Adverse Event Reporting and Analysis), Deployment (on Premise, on Demand), End Use and Region with Growth Forecasts, 2025-2033

  • Report
  • 190 Pages
  • Global
From
Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2026-2034 - Product Image

Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2026-2034

  • Report
  • 145 Pages
  • Global
From

About the Pharmacovigilance Market

The Pharmacovigilance market is a subset of the Healthcare Services industry, focusing on the monitoring and assessment of the safety of pharmaceutical products. It involves the collection, analysis, and reporting of adverse events related to the use of drugs, as well as the identification of potential risks associated with their use. Pharmacovigilance activities are conducted by pharmaceutical companies, regulatory authorities, and healthcare professionals. Pharmacovigilance activities are essential for the safe and effective use of drugs, as they help to identify potential risks and ensure that the benefits of the drug outweigh the risks. Pharmacovigilance also helps to ensure that the drug is used appropriately and that any adverse events are reported and addressed. Some companies in the Pharmacovigilance market include Parexel, Quintiles, Covance, PRA Health Sciences, and ICON. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.